Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Esketamine Market Growth in 2025?

In the past few years, there has been a swift expansion in the esketamine market size. The market is projected to surge from $1.37 billion in 2024 to $1.52 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.2%. This augmentation during the historic period is primarily due to an uptick in patient numbers, a rising global prevalence of mental health disorders, enhanced disease state awareness, growing demand for innovative treatment alternatives, and positive regulatory approvals.

What Is the Forecast for the Esketamine Market Size Through 2029?

The market size of esketamine is poised for notable acceleration in the years to come, expected to reach $2.31 billion by 2029, with a compound annual growth rate (CAGR) of 11.0%. Factors that will fuel the market growth during the forecast period include the rising cases of treatment-resistant depression, amplified focus on research and development initiatives, the need for smart healthcare frameworks, the propelling incline towards telehealth services, and the mounting recognition of esketamine as a potent treatment method. The forecast period will also see prominent trends such as collaborations between biotech enterprises and mental health associations, the application of robotics in healthcare, personalized treatment approaches, sensor-driven devices, and the opportunity for combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

What are the Key Market Players in Esketamine Market and How They’re Evolving?

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

What Are the Primary Growth Drivers in the Esketamine Market?

The escalating occurrence of treatment-resistant depression (TRD) is projected to fuel the expansion of the esketamine market in the forthcoming years. TRD characterizes a form of depression that does not exhibit enhancement after the consumption of at least two distinct antidepressant medications at correct doses over an adequate period. The surge in TRD incidences is due to the diminished effectiveness of traditional antidepressants which results in protracted and recurring depressive episodes. Esketamine aids in alleviating TRD through a rapid action mechanism that targets NMDA receptors, offering solace for patients who are unresponsive to classical antidepressants. For instance, the U.S.-based federal body, National Institute of Mental Health reported in September 2023, a resistance to standard treatments amongst about 30% of individuals suffering from major depressive disorder in the U.S. in 2023. Thus, the escalating prevalence of treatment-resistant depression accelerates the growth of the esketamine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

What Are the Leading Segments in the Global Esketamine Industry?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

What Are the Key Market Trends in the Esketamine Industry?

Leading players in the esketamine market are concentrating their efforts on creating innovative treatment methods such as monotherapy, aiming to provide better relief from depressive symptoms than what a placebo can provide. Monotherapy involves using just one specific drug or treatment regime for managing a disease or health condition, as opposed to using a combination of several treatments. A case in point is Johnson & Johnson, an American pharmaceutical firm, which announced in January 2025 that the U.S. Food and Drug Administration (FDA) had endorsed SPRAVATO (esketamine) as the exclusive monotherapy for adults struggling with treatment-resistant depression (TRD). Strongly backed by clinical research, this endorsement proved that SPRAVATO holds the potential for speeding up the alleviation of depressive symptoms, with noticeable improvements seen within 24 hours. This pioneering development brings a much-needed solution for around 30% of people who do not achieve the desired results from conventional antidepressants, effectively doing away with parallel oral medication. Although SPRAVATO has a positive safety record, it must be dispensed under a Risk Evaluation and Mitigation Strategy (REMS) to safeguard against any possible side effects. This achievement points to a crucial leap forward in the treatment of TRD, opening up the likelihood of enhanced patient results.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

What Is the Regional Outlook for the Esketamine Market?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393

This Report Delivers Insight On:

1. How big is the esketamine market, and how is it changing globally?

2. Who are the major companies in the esketamine market, and how are they performing?

3. What are the key opportunities and risks in the esketamine market right now?

4. Which products or customer segments are growing the most in the esketamine market?

5. What factors are helping or slowing down the growth of the esketamine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model